Sagent Pharmaceuticals today announced FDA approval of bupivacaine hydrochloride injection, a local or regional anesthetic, according to a MarketWatch report.
The company's bupivacaine will be available in six single-dose and two multi-dose latex-free vials. According to IMS data, the 2011 U.S. market for injectable bupivacaine approximates $29 million.
Bupivacaine is the 13th product approved under the joint venture between Sagent and Strides Arcolab. Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the U.S.
Related Articles on Anesthesia:
Gabapentin Does Not Decrease Pain After Total Knee Arthroplasty
Popliteal Blocks Cause Rebound Pain After Ankle Fracture Surgery
Type of General Anesthesia Does Not Increase Delirium in Post-Op Period
The company's bupivacaine will be available in six single-dose and two multi-dose latex-free vials. According to IMS data, the 2011 U.S. market for injectable bupivacaine approximates $29 million.
Bupivacaine is the 13th product approved under the joint venture between Sagent and Strides Arcolab. Under the collaboration, Strides is responsible for developing and supplying injectable products that Sagent will market in the U.S.
Related Articles on Anesthesia:
Gabapentin Does Not Decrease Pain After Total Knee Arthroplasty
Popliteal Blocks Cause Rebound Pain After Ankle Fracture Surgery
Type of General Anesthesia Does Not Increase Delirium in Post-Op Period